News
8th November 2017 - Royal Preston Hospital Adopts OC-Sensor
The Royal Preston Hospital, Lancashire, has adopted OC-Sensor Faecal Immunochemical Test (FIT) into their Clinical Pathology services to provide a fast, accurate method for the diagnosis of colorectal diseases.
Read more...
1st November 2017: Increased uptake rates for OC-Sensor in Spain
Basque country recently presented a poster, displaying exceptional uptake rates in the 4th consecutive round of screening; at the 2017 International Cancer Screening Network (ICSN). The poster demonstrates an overall increase in participation of men from 63.7% to 71.9% and 69.1% to 76% in women, from the 1st round to the 4th round, respectively. The importance of the first participation is demonstrated as key to the successive increase in uptake from 66.5% to 74.1%.
Read more...
4th September 2017: Cutting Edge Development
Eiken Chemical Co. is proud to announce the release of new V-PH59 LV3 Liquid Control for the OC-Sensor platform. V-PH59 complements the existing range of ready to use, liquid controls and calibrators by increasing confidence at low faecal haemoglobin concentrations often experienced in symptomatic populations.
Read more…
29th August 2017: NG12 - OC Sensor shown to be cost effective
The recent publication of the NICE Diagnostics guidance reported that OC Sensor is cost effective in the NG12 pathway when compared to other FIT, guaiac and no triage models.
Read more…
12th January 2017: Testing for colorectal cancer: A focus on FIT technology.
Approximately 41,000 people are diagnosed with colorectal cancer (CRC) in the UK each year, and over 90% of cases are treated successfully following early detection. However, to selectively refer those patients with suspected CRC in a primary care setting remains immensely challenging. The recent revision of the NICE (NG12) ‘red flag’ criteria for the two-week wait aims to increase the CRC detection rate.
Read more…
28th October 2016: Following the release of the revised NG12 Urgent cancer referral pathway in 2015, NICE have selected OC Sensor as the subject of a Health Technology Assessment for the use of FIT in patients at low risk of CRC in a primary care setting. Due for publication early in 2017.
24th October 2016: In 2014, the NHS Bowel Cancer Screening Programme (BCSP) in England ran a pilot study to assess the operational and financial implications of using Faecal Immunochemical Testing (FIT) for haemoglobin detection rather than Guaiac Faecal Occult Blood Testing (gFOBT). The results demonstrated very good correlation between the four OC-Sensor DIANA analysers used, and sets a benchmark for such analysers in a screening programme.
Read more…
24th October 2016: The NHS Bowel Cancer Screening Programme (BCSP) in England has used a guaiac-based Faecal Occult Blood Test (gFOBT) since its inception in 2006. Through the pilot study to assess the implications of adopting FIT in England, OC-Sensor and Mast® FITpac demonstrated outstanding results.
Read more…
